Barclays Maintains Overweight on Regenxbio, Lowers Price Target to $12

Benzinga Newsdesk www.benzinga.com Negative 91.1%

Neg 91.1% Neu 0% Pos 0%

Barclays analyst Gena Wang maintains Regenxbio (NASDAQ:RGNX) with a Overweight and lowers the price target from $37 to $12.